INmune Bio - INMB Stock Forecast, Price & News

INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

INmune Bio Price Performance

NASDAQ:INMB traded down $0.86 during trading hours on Tuesday, hitting $9.30. The company's stock had a trading volume of 57,811 shares, compared to its average volume of 130,594. The business's 50-day moving average is $8.69 and its two-hundred day moving average is $8.39. The company has a market capitalization of $166.90 million, a PE ratio of -4.97 and a beta of 1.92. The company has a debt-to-equity ratio of 0.21, a quick ratio of 30.87 and a current ratio of 30.87. INmune Bio has a 52-week low of $4.63 and a 52-week high of $30.37.

INmune Bio (NASDAQ:INMB - Get Rating) last released its quarterly earnings data on Wednesday, August 3rd. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.12. INmune Bio had a negative return on equity of 41.87% and a negative net margin of 9,233.15%. During the same period in the previous year, the business earned ($0.44) earnings per share. As a group, research analysts anticipate that INmune Bio will post -2.05 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. B. Riley downgraded INmune Bio from a "buy" rating to a "neutral" rating and dropped their target price for the company from $14.00 to $7.00 in a research report on Tuesday, May 24th. Maxim Group began coverage on INmune Bio in a report on Friday, May 6th. They issued a "buy" rating and a $22.00 price target for the company. Finally, BTIG Research reduced their price objective on INmune Bio from $31.00 to $14.00 and set a "buy" rating for the company in a research note on Tuesday, May 24th.

Insider Buying and Selling at INmune Bio

In other news, CFO David J. Moss bought 7,700 shares of the stock in a transaction on Thursday, May 26th. The shares were bought at an average price of $6.27 per share, with a total value of $48,279.00. Following the completion of the acquisition, the chief financial officer now owns 1,244,651 shares of the company's stock, valued at $7,803,961.77. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, CEO Raymond Joseph Tesi acquired 6,300 shares of the firm's stock in a transaction that occurred on Thursday, May 26th. The shares were acquired at an average price of $6.41 per share, with a total value of $40,383.00. Following the completion of the purchase, the chief executive officer now directly owns 1,520,698 shares in the company, valued at $9,747,674.18. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, CFO David J. Moss acquired 7,700 shares of the firm's stock in a transaction that occurred on Thursday, May 26th. The shares were bought at an average cost of $6.27 per share, for a total transaction of $48,279.00. Following the purchase, the chief financial officer now owns 1,244,651 shares of the company's stock, valued at $7,803,961.77. The disclosure for this purchase can be found here. 34.20% of the stock is owned by corporate insiders.